These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 38432433)

  • 1. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
    Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
    Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab.
    Chari A; Krishnan A; Rasche L; Ye JC; Garfall A; Popat R; Lipe B; Qin X; Campagna M; Masterson T; Tomlinson C; Hilder B; Tolbert J; Renaud T; Smit MD; Gray K; Kane C; Heuck C; van de Donk NWCJ
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):665-693.e14. PubMed ID: 38871558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma.
    Hammons L; Szabo A; Janardan A; Bhatlapenumarthi V; Annyapu E; Dhakal B; Al Hadidi S; Radhakrishnan SV; Narra R; Bhutani D; Thanendrarajan S; Janz S; Zangari M; Lentzsch S; Van Rhee F; Crescencio JCR; D'Souza A; Chakraborty R; Mohan M; Schinke C
    Haematologica; 2024 Mar; 109(3):906-914. PubMed ID: 37646658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast.
    Landgren O; Nadeem O
    Adv Ther; 2023 Aug; 40(8):3291-3303. PubMed ID: 37328635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.
    Verkleij CPM; O'Neill CA; Broekmans MEC; Frerichs KA; Bruins WSC; Duetz C; Kruyswijk S; Baglio SR; Skerget S; Montes de Oca R; Zweegman S; Verona RI; Mutis T; van de Donk NWCJ
    Clin Cancer Res; 2024 Jul; 30(14):3006-3022. PubMed ID: 38687588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of infectious complications with BCMA-directed therapies in multiple myeloma.
    Nath K; Shekarkhand T; Nemirovsky D; Derkach A; Costa BA; Nishimura N; Farzana T; Rueda C; Chung DJ; Landau HJ; Lahoud OB; Scordo M; Shah GL; Hassoun H; Maclachlan K; Korde N; Shah UA; Tan CR; Hultcrantz M; Giralt SA; Usmani SZ; Shahid Z; Mailankody S; Lesokhin AM
    Blood Cancer J; 2024 May; 14(1):88. PubMed ID: 38821925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Treatment Modality and Route of Administration on Cytokine Release Syndrome in Relapsed or Refractory Multiple Myeloma: A Meta-Analysis.
    Soltantabar P; Sharma S; Wang D; Lon HK; Czibere A; Hickmann A; Elmeliegy M
    Clin Pharmacol Ther; 2024 Jun; 115(6):1258-1268. PubMed ID: 38459622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed/refractory multiple myeloma.
    Martin TG; Mateos MV; Nooka A; Banerjee A; Kobos R; Pei L; Qi M; Verona R; Doyle M; Smit J; Sun W; Trancucci D; Uhlar C; van de Donk NWCJ; Rodriguez C
    Cancer; 2023 Jul; 129(13):2035-2046. PubMed ID: 36991547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.
    Mohan M; Monge J; Shah N; Luan D; Forsberg M; Bhatlapenumarthi V; Balev M; Patwari A; Cheruvalath H; Bhutani D; Thanendrarajan S; Dhakal B; Zangari M; Al-Hadidi S; Cooper D; Lentzsch S; van Rhee F; D'Souza A; Szabo A; Schinke C; Chakraborty R
    Blood Cancer J; 2024 Mar; 14(1):35. PubMed ID: 38443345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting GPRC5D in multiple myeloma.
    Elemian S; Al Hadidi S
    Expert Rev Anticancer Ther; 2024 May; 24(5):229-238. PubMed ID: 38607646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Siltuximab as a primary treatment for cytokine release syndrome in a patient receiving a bispecific antibody in a clinical trial setting.
    Lipe BC; Renaud T
    J Oncol Pharm Pract; 2023 Jun; 29(4):1006-1010. PubMed ID: 36464766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting.
    Zhao J; Ren Q; Liu X; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):92. PubMed ID: 37537597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
    Chari A; Minnema MC; Berdeja JG; Oriol A; van de Donk NWCJ; Rodríguez-Otero P; Askari E; Mateos MV; Costa LJ; Caers J; Verona R; Girgis S; Yang S; Goldsmith RB; Yao X; Pillarisetti K; Hilder BW; Russell J; Goldberg JD; Krishnan A
    N Engl J Med; 2022 Dec; 387(24):2232-2244. PubMed ID: 36507686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
    Usmani SZ; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Rosinol L; Chari A; Bhutani M; Karlin L; Benboubker L; Pei L; Verona R; Girgis S; Stephenson T; Elsayed Y; Infante J; Goldberg JD; Banerjee A; Mateos MV; Krishnan A
    Lancet; 2021 Aug; 398(10301):665-674. PubMed ID: 34388396
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teclistamab in Relapsed or Refractory Multiple Myeloma.
    Moreau P; Garfall AL; van de Donk NWCJ; Nahi H; San-Miguel JF; Oriol A; Nooka AK; Martin T; Rosinol L; Chari A; Karlin L; Benboubker L; Mateos MV; Bahlis N; Popat R; Besemer B; Martínez-López J; Sidana S; Delforge M; Pei L; Trancucci D; Verona R; Girgis S; Lin SXW; Olyslager Y; Jaffe M; Uhlar C; Stephenson T; Van Rampelbergh R; Banerjee A; Goldberg JD; Kobos R; Krishnan A; Usmani SZ
    N Engl J Med; 2022 Aug; 387(6):495-505. PubMed ID: 35661166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
    Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
    Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor and bispecific T-cell engager therapies in multiple myeloma patients with prior allogeneic transplantation.
    Hammons L; Haider S; Portuguese AJ; Banerjee R; Szabo A; Pasquini M; Chhabra S; Radhakrishnan S; Mohan M; Narra R; Dong J; Janz S; Shah NN; Hamadani M; D'Souza A; Hari P; Dhakal B
    Br J Haematol; 2024 Mar; 204(3):887-891. PubMed ID: 38054558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nursing Considerations for the Clinical Management of Adverse Events Associated with Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma.
    Catamero D; Ray C; Purcell K; Leahey S; Esler E; Rogers S; Hefner K; O'Rourke L; Gray K; Tolbert J; Renaud T; Patel S; Hannemann L; Shenoy S
    Semin Oncol Nurs; 2024 Oct; 40(5):151712. PubMed ID: 39155155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of bispecific antibodies therapy for relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials.
    Wang X; Zhao A; Zhu J; Niu T
    Front Immunol; 2024; 15():1348955. PubMed ID: 38482019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.